An Old Drug Renewed: What is Happening with mIBG?

Sunday, March 24, 2024

2:15 PM – 4:15 PM East Coast USA Time

Location: Orange County Convention Center, W314B

CE: 2.0

ACPE Number: 0202-0000-24-097-L99-P

Number of Hours: 2

Activity Type: Knowledge

Speaker(s)

Anne Ellis, NMAA, CNMT (she/her/hers)

Nuclear Medicine Technologist, MIBG Study Coordinator
University of Michigan-Michigan Medicine
Ann Arbor, Michigan, United States
Hannah E. Sauer, PharmD, BCOP (she/her/hers)

Clinical Pharmacy Specialist
St. Jude Children's Research Hospital
Crosby, Texas, United States

Handout

Disclosure(s):

Anne Ellis, NMAA, CNMT: No financial relationships to disclose

Hannah E. Sauer, PharmD, BCOP: No financial relationships to disclose

MIBG has been around for quite a while, but it still garners interest from treating physicians. Attend this session to hear about current mIBG use as well as review disease states that can utilize mIBG in their treatment plans.

Learning Objectives:

Describe disease states that can be effectively diagnosed with radiolabeled mIBG
Discuss the role of radiolabeled mIBG and radiolabeld dotatate in the treatment of disease
Discuss the availability of radiolabeled mIBG diagnostic and therapeutic radiopharmaceuticals
Explain the distribution of radiolabeled mIBG and its metabolites
Describe patient safety when administered radiolabeled mIBG